NKCFO LLC’s Maravai LifeSciences MRVI Stock Holding History

NKCFO LLC’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,412	Closed	-$101K	–	138
2021 Q4	$101K	Buy	+2,412	New	+$97.7K	0.03%	82

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NKCFO LLC's MRVI Position: Q1 2022 in Review

NKCFO LLC sold out of Maravai LifeSciences (MRVI) in Q1 2022, closing a stake of 2,412 shares — an estimated $101K sold.

NKCFO LLC first reported a position in MRVI in Q4 2021 and held it in 1 quarter. The position peaked at $101K in Q4 2021. 235 funds tracked by Wall St. Rank hold MRVI as of Q1 2022.

NKCFO LLC reported no remaining Maravai LifeSciences position as of Q1 2022 after selling out during the quarter.
NKCFO LLC sold 2,412 Maravai LifeSciences shares in Q1 2022, an estimated $101K.
NKCFO LLC first reported a position in Maravai LifeSciences in Q4 2021 and held it in 1 quarter.
NKCFO LLC's Maravai LifeSciences position peaked at $101K in Q4 2021.
235 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2022.

Based on NKCFO LLC's 13F filing for Q1 2022, filed 28 Apr 2022.